MCID: 49X010
MIFTS: 34

49,xxxxx Syndrome

Categories: Fetal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for 49,xxxxx Syndrome

MalaCards integrated aliases for 49,xxxxx Syndrome:

Name: 49,xxxxx Syndrome 19 58
Pentasomy X 19 58 75
Chromosome Xxxxx Syndrome 19
Chromosome X Pentasomy 19
Pentasomy X Syndrome 19
49, Xxxxx Syndrome 75
Penta-X Syndrome 19
Penta X Syndrome 75
Xxxxx Syndrome 75
49,xxxxx 75
Penta-X 58
Poly-X 58

Characteristics:


Age Of Onset:

Pentasomy X: Neonatal 58

Classifications:

Orphanet: 58  
Developmental anomalies during embryogenesis


Summaries for 49,xxxxx Syndrome

GARD: 19 Pentasomy X is a sex chromosome anomaly caused by the presence of three extra X chromosomes in females (49,XXXXX instead of 46,XX).

MalaCards based summary: 49,xxxxx Syndrome, also known as pentasomy x, is related to 49, xxxxy syndrome and turner syndrome. The drugs Immunologic Factors and Heptavalent Pneumococcal Conjugate Vaccine have been mentioned in the context of this disorder. Affiliated tissues include heart, breast and colon, and related phenotypes are hypotonia and low-set, posteriorly rotated ears

Orphanet: 58 Pentasomy X is a sex chromosome anomaly caused by the presence of three extra X chromosomes in females (49,XXXXX instead of 46,XX).

Wikipedia: 75 Pentasomy X, also known as 49,XXXXX, is a chromosomal disorder in which a female has five, rather than... more...

Related Diseases for 49,xxxxx Syndrome

Diseases related to 49,xxxxx Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
# Related Disease Score Top Affiliating Genes
1 49, xxxxy syndrome 10.5
2 turner syndrome 10.2
3 patent ductus arteriosus 1 10.1
4 47 xxx syndrome 10.1
5 hypertelorism 10.1
6 down syndrome 10.1
7 synostosis 10.1
8 radioulnar synostosis 10.1
9 microcephaly 10.1
10 cleft palate, isolated 10.1
11 hydrocephalus 10.1
12 epicanthus 10.0
13 nondisjunction 10.0
14 heart septal defect 10.0
15 atrial heart septal defect 10.0
16 myocarditis 10.0
17 48,xyyy 10.0
18 tetrasomy x 10.0
19 hypotonia 10.0
20 interatrial communication 10.0
21 hemifacial hyperplasia 9.9
22 larsen syndrome 9.9
23 dandy-walker syndrome 9.9
24 type 1 diabetes mellitus 9.9
25 hydrocephalus, congenital, 1 9.9
26 hydrops fetalis, nonimmune 9.9
27 arts syndrome 9.9
28 scoliosis 9.9
29 ptosis 9.9
30 renal hypoplasia 9.9
31 hyper ige syndrome 9.9
32 leukodystrophy 9.9
33 premature menopause 9.9
34 pyelonephritis 9.9
35 amenorrhea 9.9
36 ventricular septal defect 9.9
37 status epilepticus 9.9
38 dermatitis 9.9
39 hyper ige recurrent infection syndrome 1 9.9
40 polyhydramnios 9.9
41 immune hydrops fetalis 9.9
42 sex-chromosome anomaly 9.9
43 hypoglycemia 9.9
44 helix syndrome 9.8

Graphical network of the top 20 diseases related to 49,xxxxx Syndrome:



Diseases related to 49,xxxxx Syndrome

Symptoms & Phenotypes for 49,xxxxx Syndrome

Human phenotypes related to 49,xxxxx Syndrome:

58 30 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypotonia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001252
2 low-set, posteriorly rotated ears 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000368
3 intellectual disability 58 30 Frequent (33%) Frequent (79-30%)
HP:0001249
4 global developmental delay 58 30 Frequent (33%) Frequent (79-30%)
HP:0001263
5 hypertelorism 58 30 Frequent (33%) Frequent (79-30%)
HP:0000316
6 wide nasal bridge 58 30 Frequent (33%) Frequent (79-30%)
HP:0000431
7 microcephaly 58 30 Frequent (33%) Frequent (79-30%)
HP:0000252
8 short stature 58 30 Frequent (33%) Frequent (79-30%)
HP:0004322
9 strabismus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000486
10 micrognathia 58 30 Frequent (33%) Frequent (79-30%)
HP:0000347
11 upslanted palpebral fissure 58 30 Frequent (33%) Frequent (79-30%)
HP:0000582
12 clinodactyly of the 5th finger 58 30 Frequent (33%) Frequent (79-30%)
HP:0004209
13 radioulnar synostosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002974
14 small hand 58 30 Frequent (33%) Frequent (79-30%)
HP:0200055
15 camptodactyly of finger 58 30 Frequent (33%) Frequent (79-30%)
HP:0100490
16 plagiocephaly 58 30 Frequent (33%) Frequent (79-30%)
HP:0001357
17 short foot 58 30 Frequent (33%) Frequent (79-30%)
HP:0001773
18 hip dysplasia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001385
19 delayed puberty 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000823
20 abnormality of immune system physiology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010978
21 patent ductus arteriosus 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001643
22 abnormal cardiac septum morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001671

Drugs & Therapeutics for 49,xxxxx Syndrome

Drugs for 49,xxxxx Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4
2 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
3
Cocaine Approved, Illicit Phase 3 50-36-2 446220 5760
4
Aluminium phosphate Approved, Investigational Phase 3 7784-30-7
5
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 4659387 5311101
6 Hemagglutinins Phase 3
7 Agglutinins Phase 3
8 Bronchodilator Agents Phase 2, Phase 3
9 Anti-Asthmatic Agents Phase 2, Phase 3
10 Anti-Allergic Agents Phase 2, Phase 3
11 Xhance Phase 2, Phase 3
12 Respiratory System Agents Phase 2, Phase 3
13 Anti-Inflammatory Agents Phase 2, Phase 3
14 Dermatologic Agents Phase 2, Phase 3
15 polysaccharide-K Phase 3
16
Rituximab Approved Phase 2 174722-31-7
17
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
18
Aflibercept Approved Phase 2 862111-32-8 124490314
19
Fluorouracil Approved Phase 2 51-21-8 3385
20
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
21
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
22
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
25
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
26
Sargramostim Approved, Investigational Phase 2 123774-72-1
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28
Epratuzumab Investigational Phase 2 205923-57-5
29
Molgramostim Investigational Phase 2 99283-10-0
30 Antirheumatic Agents Phase 2
31 Immunoglobulins Phase 2
32 Antibodies, Monoclonal Phase 2
33 Antibodies Phase 2
34 N-(2-aminoethyl)-5-isoquinolinesulfonamide Phase 1, Phase 2
35 Angiogenesis Inhibitors Phase 2
36 Antineoplastic Agents, Immunological Phase 2
37 Folate Phase 2
38 Vitamin B9 Phase 2
39 Vitamin B Complex Phase 2
40 Folic Acid Antagonists Phase 2
41 Albumin-Bound Paclitaxel Phase 2
42 Antimitotic Agents Phase 2
43 Tubulin Modulators Phase 2
44
Metformin Approved Phase 1 1115-70-4, 657-24-9 4091
45
Aluminum sulfate Approved Phase 1 10043-01-3
46
Ethanol Approved 64-17-5 702
47
Bortezomib Approved, Investigational 179324-69-7 387447 93860
48
Iron Approved 7439-89-6 29936
49
Iodine Approved, Investigational 7553-56-2 807
50
Mecobalamin Approved, Investigational 13422-55-4

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (IIV) in Adults 18-49 Years of Age Completed NCT03101462 Phase 4
2 An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age Completed NCT00192140 Phase 4
3 A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 TO 49 YEARS OF AGE IN INDIA Active, not recruiting NCT05329259 Phase 4
4 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age Unknown status NCT00216242 Phase 3
5 Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok® Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age Completed NCT02290509 Phase 3
6 A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE Completed NCT03828617 Phase 3
7 A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age. Completed NCT05045144 Phase 3
8 A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age Completed NCT00860067 Phase 2, Phase 3
9 A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent Virus-Like Particle Influenza Vaccine in Healthy Adults 18-49 Years of Age Completed NCT03321968 Phase 3
10 Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 Years Completed NCT00539981 Phase 3
11 A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age Completed NCT00952705 Phase 3
12 A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY) Completed NCT03547167 Phase 3
13 A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years Completed NCT00192335 Phase 3
14 A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Consistency of Three Consecutive Lots of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs in Healthy Subjects Aged 18 to 49 Years Completed NCT00617851 Phase 3
15 Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. Completed NCT00328107 Phase 2, Phase 3
16 A Phase II/III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 18-49 Years Completed NCT03390166 Phase 2, Phase 3
17 A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population Completed NCT01734239 Phase 3
18 A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old Recruiting NCT05054322 Phase 2, Phase 3 Fluticasone Propionate
19 Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. Recruiting NCT05513053 Phase 3
20 A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age Active, not recruiting NCT04605159 Phase 3 Placebo
21 A Phase III, Randomized, Open-label, Active Vaccine-controlled Crossover Study to Evaluate the Reactogenicity, Safety and Immune Response of Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Girls From 9 to 17 Years of Age, and in Non-pregnant Adult Women From 18 to 49 Years of Age Active, not recruiting NCT05169905 Phase 3
22 A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age Active, not recruiting NCT05464420 Phase 3
23 A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers Active, not recruiting NCT04980391 Phase 3 Placebo
24 A Randomized, Observer-Blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-49 Years of Age Not yet recruiting NCT05040789 Phase 3
25 A Phase IIIB, Open Label, Non-randomized, Controlled, Multi-country Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Repeat Vaccination With 120 µg Dose of RSV Maternal Vaccine During Subsequent Pregnancy in Healthy Maternal Participants 18-49 Years of Age Withdrawn NCT05229068 Phase 3
26 A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Completed NCT00553501 Phase 2
27 A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE Completed NCT04071158 Phase 2
28 Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years Completed NCT02669121 Phase 2
29 Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years Completed NCT00845429 Phase 2
30 A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults Completed NCT02307851 Phase 2
31 A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85 Completed NCT04473690 Phase 1, Phase 2
32 A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS Completed NCT04032093 Phase 2
33 A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49 Completed NCT01147068 Phase 1, Phase 2
34 A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE Completed NCT03170609 Phase 2
35 Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years Completed NCT01612000 Phase 1, Phase 2
36 Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age Completed NCT00623181 Phase 2
37 A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 Years to 49 Years Completed NCT02894840 Phase 1, Phase 2
38 A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older. Completed NCT01224262 Phase 1, Phase 2
39 A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years Completed NCT01320696 Phase 1, Phase 2
40 OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study. Completed NCT01802684 Phase 2
41 A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49% Recruiting NCT04856176 Phase 2 Granulocyte-Macrophage Colony-Stimulating Factor;Pembrolizumab;pemetrexed;Paclitaxel;Carboplatin
42 A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE Active, not recruiting NCT04766086 Phase 2
43 A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain Not yet recruiting NCT05560646 Phase 2 OG-6219;Placebo
44 Phase I Randomized Double Blind Placebo-controlled Study of Universal Influenza Vector Vaccine "UniFluVec" of Two Dose Levels After Two Intranasal Administrations in Healthy Volunteers at the Age From 18 to 49 Years Old Completed NCT04650971 Phase 1
45 A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet β-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Completed NCT01933256 Phase 1 HIP2B;Placebo
46 A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age Completed NCT00641017 Phase 1
47 A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study Completed NCT00730457 Phase 1
48 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years Completed NCT03343626 Phase 1 Placebo
49 A Phase 1, Randomized, Controlled, Observer-blinded Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults Aged 18 To 49 Years Completed NCT02955160 Phase 1
50 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years. Completed NCT00599443 Phase 1

Search NIH Clinical Center for 49,xxxxx Syndrome

Genetic Tests for 49,xxxxx Syndrome

Anatomical Context for 49,xxxxx Syndrome

Organs/tissues related to 49,xxxxx Syndrome:

MalaCards : Heart, Breast, Colon, Lung

Publications for 49,xxxxx Syndrome

Articles related to 49,xxxxx Syndrome:

(show top 50) (show all 71)
# Title Authors PMID Year
1
Modeling the spectral properties of poly(x-phenylenediamine) conducting polymers using a combined TD-DFT and electrostatic embedding approach. 62
35762850 2022
2
Non-Invasive Prenatal Screening: The First Report of Pentasomy X Detected by Plasma Cell-Free DNA and Karyotype Analysis. 62
35885497 2022
3
Report of a New Case of Pentasomy X Revealed by Status Epilepticus. 62
34367739 2021
4
Tuning the Reactivity and Bonding Properties of Metal Square-Planar Complexes by the Substitution(s) on the Trans-Coordinated Pyridine Ring. 62
32478268 2020
5
The type and prevalence of chromosomal abnormalities in couples with recurrent first trimester abortions: A Turkish retrospective study. 62
31085277 2019
6
The Effect of the Isomeric Chlorine Substitutions on the Honeycomb-Patterned Films of Poly(x-chlorostyrene)s/Polystyrene Blends and Copolymers via Static Breath Figure Technique. 62
30621027 2019
7
[Examination of sex chromosome abnormalities in childhood]. 62
29961370 2018
8
A case of penta X syndrome caused by nondisjunction in maternal meiosis 1 and 2. 62
28680612 2017
9
Jump transition observed in translocation time for ideal poly-X proteinogenic chains as a result of competing folding and anchoraging contributions. 62
28208414 2017
10
Differential Diagnosis of Genetic Disorders Associated with Moderate to Severe Refractory Eczema and Elevated Immunoglobulin E. 62
26593686 2016
11
Report of a new case with pentasomy X and novel clinical findings. 62
26929910 2015
12
A JAZ Protein in Astragalus sinicus Interacts with a Leghemoglobin through the TIFY Domain and Is Involved in Nodule Development and Nitrogen Fixation. 62
26460857 2015
13
A new case of prenatally diagnosed pentasomy x: review of the literature. 62
25699192 2015
14
Thermodynamics of ideal proteinogenic homopolymer chains as a function of the energy spectrum E, helical propensity ω and enthalpic energy barrier. 62
23515207 2013
15
Transient hydrops fetalis in a prenatally diagnosed pentasomy X? 62
22612635 2012
16
Dosage effects of X and Y chromosomes on language and social functioning in children with supernumerary sex chromosome aneuploidies: implications for idiopathic language impairment and autism spectrum disorders. 62
22827287 2012
17
Development of an Interaction Assay between Single-Stranded Nucleic Acids Trapped with Silica Particles and Fluorescent Compounds. 62
24955635 2012
18
Deca-heterosubstituted corannulenes. 62
22543307 2012
19
Mosaic pentasomy X/tetrasomy X syndrome and premature ovarian failure. 62
21654007 2011
20
A review of trisomy X (47,XXX). 62
20459843 2010
21
Detailed analysis of X chromosome inactivation in a 49,XXXXX pentasomy. 62
19811657 2009
22
A case of 49,XXXXX in which the extra X chromosomes were maternal in origin. 62
15333671 2004
23
Xanthine, xanthosine and its nucleotides: solution structures of neutral and ionic forms, and relevance to substrate properties in various enzyme systems and metabolic pathways. 62
15218545 2004
24
[Sex chromosome abnormality: report of three clinical cases of X pentasomy]. 62
15080523 2003
25
Cleft lip and/or palate in two cases of 46,X,i(Xq) Turner syndrome. 62
12017233 2002
26
[Chromosome X, poly-X]. 62
11462510 2001
27
Pentasomy X and hyper IgE syndrome: co-existence of two distinct genetic disorders. 62
10485303 1999
28
Modeling protein homopolymeric repeats: possible polyglutamine structural motifs for Huntington's disease. 62
9783215 1998
29
Sex chromosome tetrasomy and pentasomy. 62
7567329 1995
30
Dandy-Walker malformation in a fetus with pentasomy X (49,XXXXX) prenatally diagnosed by fluorescence in situ hybridization technique. 62
7576173 1995
31
On the parental origin of the X's in a prenatally diagnosed 49,XXXXX syndrome. 62
8284294 1993
32
Pentasomy X mosaic in two adult sisters with diabetes mellitus. 62
1421717 1992
33
[Pentasomy X: a clinical case report]. 62
1362611 1992
34
Penta X syndrome: a case report with review of the literature. 62
1887850 1991
35
Polypeptide models of elastin: CD and NMR studies on synthetic poly(X-Gly-Gly). 62
1742165 1991
36
[Penta-X syndrome. Report of a case with 47,XXX/48,XXXX/49,XXXXX mosaicism]. 62
2665783 1989
37
Lanthanide ions as luminescent chromophores for the liquid chromatographic detection of polynucleotides and nucleic acids. 62
3356764 1988
38
Nuclease recognition of an alternating structure in a d(AT)14 plasmid insert. 62
3012479 1986
39
Formylmethionyl-tRNA binding to 30 S ribosomes programmed with homopolynucleotides and the effect of translational initiation factor 3. 62
3513840 1986
40
Metabolic activation of 1-nitropyrene and 1,6-dinitropyrene by nitroreductases from Bacteroides fragilis and distribution of nitroreductase activity in rats. 62
3796318 1986
41
Chymotrypsin treatment of glucocorticoid receptor attenuates RNA-dependent inhibition of DNA binding. Evidence for a distinct RNA-binding site. 62
2411295 1985
42
Oral and dental development in X chromosome aneuploidy. 62
3978846 1985
43
Interaction of poly(X) with poly(U): alkali metal ion specificity suggests a four-stranded helix. 62
6626690 1983
44
A case of 49, XXXXX syndrome. 62
6819931 1982
45
Balanced translocation karyotypes in patients with repetitive abortion. Case study and literature review. 62
7051833 1982
46
The interactions of androgen receptor with poly(A)-containing RNA and polyribonucleotides. 62
6178587 1982
47
49,XXXXX syndrome. 62
6982661 1982
48
Pentasomy X: report of patient and studies of X-inactivation. 62
7246603 1981
49
The penta-X syndrome. 62
7218280 1980
50
[A new case of pentasomy X]. 62
6773908 1980

Variations for 49,xxxxx Syndrome

Expression for 49,xxxxx Syndrome

Search GEO for disease gene expression data for 49,xxxxx Syndrome.

Pathways for 49,xxxxx Syndrome

GO Terms for 49,xxxxx Syndrome

Sources for 49,xxxxx Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....